Akebia Therapeutics is refocusing on Vafseo for dialysis patients, discontinuing expansion to non-dialysis, which has reset ...
This agreement reinforces Credence’s role as a trusted partner to the pharmaceutical industry in advancing patient care. This ...
DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or ...
Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028DURHAM, N.C., Jan. 08, 2026 (GLOBE ...
The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medicines for rare hematologic diseases: Qfitlia (fitusiran) for haemophilia and Cablivi (caplacizumab) ...
Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a year Cablivi, the first Nanobody medicine, targets ...
Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six ...
When it comes to feeding and dosing, everything starts with the rate specification. It’s a min/max ingredient level, expressed as a percentage rate of ingredient/resin rate for extrusion (3% of 500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback